Authorised

GABBROVET MULTI 140 MG/ML SOLUTION FOR USE IN DRINKING WATER/ MILK FOR PRE-RUMINANT CATTLE AND PIGS

Paromomycin sulfate

Product identification

Medicine name:

Gabbrovet Multi 140 mg/ml oldat ivóvízbe vagy tejbe keveréshez, kifejlett bendőflórával még nem rendelkező szarvasmarhák GABBROVET MULTI 140 MG/ML SOLUTION FOR USE IN DRINKING WATER/ MILK FOR PRE-RUMINANT CATTLE AND PIGS

Active substance:

Paromomycin sulfate

Target species:

Cattle (calf)

Pig

Route of administration:

Oral use

Product details

Active substance and strength:

Pharmaceutical form:

Solution for use in drinking water/milk

Withdrawal period by route of administration:

Oral use:

- Cattle (calf)
 - Meat and offal. 110 day

Cattle (pre-ruminant cattle and newborn calves): - Cryptosporidiosis: Dosage: 150 mg/kg/day for 5 days. Meat and offal: 110 days

- Meat and offal. 20 day

Cattle (pre-ruminant cattle and newborn calves): - Colibacillosis: Dosage: 25-50 mg/kg/day for 3 to 5 days. Meat and offal: 20 days

- Pig
 - Meat and offal. 3 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QA07AA06

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Hungary

Package description:

Cardboard box containing 1 bottle of 1 L containing a dosing device of 30 ml Cardboard box containing 1 bottle of 500 ml containing a dosing device of 30 ml Cardboard box containing 1 bottle of 250 ml containing a dosing device of 30 ml Cardboard box containing 1 bottle of 125 ml containing a dosing device of 30 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Ceva-Phylaxia Zrt.

Marketing authorisation date:

24/10/2022

Manufacturing sites for batch release:

Ceva Sante Animale

Responsible authority:

Directorate Of Veterinary Medicinal Products

Authorisation number:

4339/X/22 NÉBIH ÁTI

Date of authorisation status change:

24/10/2022

Reference member state:

France

Procedure number:

FR/V/0429/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland) To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Source URL: https://medicines.health.europa.eu/veterinary/600000096434